WO2003097697A3 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same - Google Patents

Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same Download PDF

Info

Publication number
WO2003097697A3
WO2003097697A3 PCT/EP2003/005324 EP0305324W WO03097697A3 WO 2003097697 A3 WO2003097697 A3 WO 2003097697A3 EP 0305324 W EP0305324 W EP 0305324W WO 03097697 A3 WO03097697 A3 WO 03097697A3
Authority
WO
WIPO (PCT)
Prior art keywords
frameworks
methods
demonstrate enhanced
enhanced stability
intracellular environment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/005324
Other languages
French (fr)
Other versions
WO2003097697A2 (en
Inventor
Kathrin Tissot
Stefan Ewert
Der Maur Adrian Auf
Alcide Barberis
Dominik Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN038146266A priority Critical patent/CN1662556B/en
Priority to AU2003238370A priority patent/AU2003238370B2/en
Priority to US10/515,241 priority patent/US8853362B2/en
Priority to HK05104060.2A priority patent/HK1071378B/en
Priority to EP03732434A priority patent/EP1506236B1/en
Priority to NZ536412A priority patent/NZ536412A/en
Priority to CA2483285A priority patent/CA2483285C/en
Priority to SI200332253T priority patent/SI1506236T1/en
Priority to JP2004506369A priority patent/JP2006508638A/en
Priority to CN201510685456.0A priority patent/CN105175535A/en
Priority to ES03732434T priority patent/ES2399617T3/en
Priority to EP15160739.7A priority patent/EP2947095B1/en
Priority to EP19200477.8A priority patent/EP3656787A1/en
Priority to DK03732434.0T priority patent/DK1506236T3/en
Application filed by Esbatech AG filed Critical Esbatech AG
Publication of WO2003097697A2 publication Critical patent/WO2003097697A2/en
Anticipated expiration legal-status Critical
Publication of WO2003097697A3 publication Critical patent/WO2003097697A3/en
Priority to AU2010202634A priority patent/AU2010202634B2/en
Priority to AU2012211497A priority patent/AU2012211497C1/en
Priority to US14/469,276 priority patent/US9518108B2/en
Priority to US15/340,195 priority patent/US10125186B2/en
Priority to US16/175,002 priority patent/US10570190B2/en
Priority to US16/716,137 priority patent/US20200165322A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
PCT/EP2003/005324 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same Ceased WO2003097697A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EP19200477.8A EP3656787A1 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US10/515,241 US8853362B2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK05104060.2A HK1071378B (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
EP03732434A EP1506236B1 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
NZ536412A NZ536412A (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CA2483285A CA2483285C (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2003238370A AU2003238370B2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
JP2004506369A JP2006508638A (en) 2002-05-22 2003-05-21 Immunoglobulin framework with improved stability in the intracellular environment and method for identifying the same
CN201510685456.0A CN105175535A (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
ES03732434T ES2399617T3 (en) 2002-05-22 2003-05-21 Immunoglobulin framework regions demonstrating enhanced stability in the intracellular environment and their identification methods
EP15160739.7A EP2947095B1 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CN038146266A CN1662556B (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks exhibiting enhanced stability in the intracellular environment and methods for their identification
SI200332253T SI1506236T1 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
DK03732434.0T DK1506236T3 (en) 2002-05-22 2003-05-21 IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF
AU2010202634A AU2010202634B2 (en) 2002-05-22 2010-06-24 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2012211497A AU2012211497C1 (en) 2002-05-22 2012-08-01 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US14/469,276 US9518108B2 (en) 2002-05-22 2014-08-26 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US15/340,195 US10125186B2 (en) 2002-05-22 2016-11-01 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US16/175,002 US10570190B2 (en) 2002-05-22 2018-10-30 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US16/716,137 US20200165322A1 (en) 2002-05-22 2019-12-16 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US60/382,649 2002-05-22
US43825603P 2003-01-03 2003-01-03
US60/438,256 2003-01-03

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/515,241 A-371-Of-International US8853362B2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
EP10010455.3A Previously-Filed-Application EP2314622B1 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US14/469,276 Division US9518108B2 (en) 2002-05-22 2014-08-26 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Publications (2)

Publication Number Publication Date
WO2003097697A2 WO2003097697A2 (en) 2003-11-27
WO2003097697A3 true WO2003097697A3 (en) 2004-12-09

Family

ID=29553590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005324 Ceased WO2003097697A2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Country Status (14)

Country Link
US (5) US8853362B2 (en)
EP (5) EP3656787A1 (en)
JP (10) JP2006508638A (en)
CN (4) CN105175535A (en)
AU (2) AU2003238370B2 (en)
CA (2) CA2867542C (en)
CY (1) CY1114225T1 (en)
DK (2) DK2332989T3 (en)
ES (3) ES2656427T3 (en)
HU (1) HUE048922T2 (en)
NZ (1) NZ536412A (en)
PT (2) PT2332989E (en)
SI (2) SI2332989T1 (en)
WO (1) WO2003097697A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US11028181B2 (en) 2015-11-12 2021-06-08 Seagen Inc. Glycan-interacting compounds and methods of use
US11253609B2 (en) 2017-03-03 2022-02-22 Seagen Inc. Glycan-interacting compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
DK2390267T3 (en) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stable and soluble antibodies that inhibit TNF (alpha)
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
EP2013236B1 (en) * 2006-04-28 2015-06-17 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
AU2007272224B2 (en) 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
CN103275216B (en) * 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 Sequence based engineering and optimization of single chain antibodies
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
KR101530723B1 (en) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 Engineering processing and optimization based on single-chain antibody sequence
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
CN101842388B (en) 2007-09-13 2013-09-04 德勒尼克斯治疗股份公司 Humanized antibodies against the beta-amyloyd peptide
HUE038432T2 (en) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
ES2771150T3 (en) * 2008-06-25 2020-07-06 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
ES2890405T3 (en) 2008-06-25 2022-01-19 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
ES2687259T5 (en) * 2008-06-25 2022-10-14 Novartis Ag Stable and soluble antibodies that inhibit TNF
HRP20241467T1 (en) 2008-06-25 2025-01-03 Novartis Ag STABLE AND SOLUBLE VEGF-INHIBITING ANTIBODIES
US9556265B2 (en) 2008-06-25 2017-01-31 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
CA2729185A1 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for modifying immunobinders
EP2303230A2 (en) 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Methods and compositions for enhanced delivery of macromolecules
RU2577965C2 (en) * 2009-02-24 2016-03-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Method of identification of immune binders for surface antigens of cells
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
UY33679A (en) 2010-10-22 2012-03-30 Esbatech STABLE AND SOLUBLE ANTIBODIES
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
AR088403A1 (en) 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc ANTIBODY OF UNION TO STABLE MULTIPLE ANTIGENS
WO2014030780A1 (en) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
US9404930B2 (en) 2012-11-05 2016-08-02 Delenex Therapeutics Ag Antibody to human IL-1 beta
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
JP2016506974A (en) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Acceptor framework for CDR grafting
HK1219485A1 (en) 2013-02-20 2017-04-07 Esbatech - A Novartis Company Llc Acceptor framework for cdr grafting
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018004515A (en) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Antibody agents specific for human cd19 and uses thereof.
CN116059316A (en) 2015-10-23 2023-05-05 优瑞科生物技术公司 Antibody/T cell receptor chimeric constructs and uses thereof
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
AU2017331256B2 (en) 2016-09-21 2024-11-07 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN112218621A (en) * 2018-04-10 2021-01-12 西北大学 Extracellular vesicles containing membrane proteins targeting affinity domains
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US11524998B2 (en) 2020-07-16 2022-12-13 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3172265A1 (en) 2021-03-10 2022-09-15 Dimitri BIELI Antibodies against tdp-43 and methods of using the same
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (en) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Method for modifying the stability of antibodies
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (en) 1995-08-18 2002-07-15 Morphosys Ag PROTEIN/(POLY)PEPTIDE LIBRARIES
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
ATE273323T1 (en) 1999-12-28 2004-08-15 Esbatech Ag INTRABODY WITH DEFINED STRUCTURE (ßFRAMEWORKß) STABLE IN A REDUCING ENVIRONMENT AND THEIR USES
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (en) 2000-08-10 2002-01-17 Infineon Technologies Ag HF input stage for television tuner has HF coupling element for parallel supply of HF resonance circuits for different reception bands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VISINTIN MICHELA ET AL: "The intracellular antibody capture technology (IACT): Towards a consensus sequence for intracellular antibodies.", JOURNAL OF MOLECULAR BIOLOGY, vol. 317, no. 1, 2002, 15 March, 2002, pages 73 - 83, XP002251365, ISSN: 0022-2836 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use
US11028181B2 (en) 2015-11-12 2021-06-08 Seagen Inc. Glycan-interacting compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US11253609B2 (en) 2017-03-03 2022-02-22 Seagen Inc. Glycan-interacting compounds and methods of use

Also Published As

Publication number Publication date
HK1217712A1 (en) 2017-01-20
EP1506236B1 (en) 2013-01-23
JP2020171286A (en) 2020-10-22
JP2010187678A (en) 2010-09-02
US20170107272A1 (en) 2017-04-20
SI2947095T1 (en) 2020-04-30
US9518108B2 (en) 2016-12-13
DK1506236T3 (en) 2013-03-04
AU2010202634B2 (en) 2012-08-23
EP3656787A1 (en) 2020-05-27
JP2015214583A (en) 2015-12-03
CN1662556A (en) 2005-08-31
CN103739706B (en) 2015-11-18
ES2537104T3 (en) 2015-06-02
NZ536412A (en) 2008-10-31
PT2332989E (en) 2015-08-05
EP1506236A2 (en) 2005-02-16
AU2003238370A1 (en) 2003-12-02
CA2483285C (en) 2015-01-27
HK1071378A1 (en) 2005-07-15
EP2314622B1 (en) 2017-10-18
JP2013256533A (en) 2013-12-26
US10570190B2 (en) 2020-02-25
US20150057191A1 (en) 2015-02-26
EP2314622A1 (en) 2011-04-27
CA2483285A1 (en) 2003-11-27
JP2012228272A (en) 2012-11-22
JP6261136B2 (en) 2018-01-17
CA2867542C (en) 2020-04-14
CY1114225T1 (en) 2016-08-31
WO2003097697A2 (en) 2003-11-27
EP2332989B1 (en) 2015-04-01
US20190119361A1 (en) 2019-04-25
US20200165322A1 (en) 2020-05-28
EP2332989A1 (en) 2011-06-15
CN102093477B (en) 2014-02-26
JP2006508638A (en) 2006-03-16
CN102093477A (en) 2011-06-15
EP2947095B1 (en) 2019-10-02
AU2003238370B2 (en) 2010-04-29
CN1662556B (en) 2013-05-01
JP2015227372A (en) 2015-12-17
US10125186B2 (en) 2018-11-13
JP6918033B2 (en) 2021-08-11
AU2010202634A1 (en) 2010-07-15
US8853362B2 (en) 2014-10-07
JP2019058191A (en) 2019-04-18
CN103739706A (en) 2014-04-23
CN105175535A (en) 2015-12-23
EP2947095A1 (en) 2015-11-25
DK2332989T3 (en) 2015-05-11
JP2017201990A (en) 2017-11-16
CA2867542A1 (en) 2003-11-27
ES2656427T3 (en) 2018-02-27
PT1506236E (en) 2013-03-27
ES2399617T3 (en) 2013-04-02
JP6075836B2 (en) 2017-02-08
SI2332989T1 (en) 2015-06-30
HUE048922T2 (en) 2020-09-28
JP6100544B2 (en) 2017-03-22
US20060035320A1 (en) 2006-02-16
JP2013078343A (en) 2013-05-02
HK1152320A1 (en) 2012-02-24

Similar Documents

Publication Publication Date Title
WO2005123277A3 (en) Optical films and methods of making the same
AU2003291180A1 (en) Transportable contaminated remains pouch
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2005058283A3 (en) Stabilised compositions of factor vii polypeptides
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
AU2001264729A1 (en) Thromboxane inhibitors, compositions and methods of use related applications
WO2004109446A3 (en) A system and method for multiple node display
CY1114225T1 (en) FRESH FRAMES WHICH PRESENT STRENGTHENED STABILITY IN THE INTELLIGENCE ENVIRONMENT AND METHODS OF IDENTIFICATION
AU2003237170A1 (en) Systems, methods, and compositions for achieving closure of vascular puncture sites
WO2006042206A3 (en) Systems and methods for direct restoration of foraminal volume
AU2003209500A1 (en) High temperature seawater-based cross-linked fracturing fluids and methods
WO2007005950A3 (en) Searching data storage systems and devices
WO2003093269A3 (en) Substituted pyrazolo-pyrimidine-4-ones
WO2007076062A3 (en) Protein formulations with reduced viscosity and uses thereof
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2007050474A3 (en) Altitude correction of a navigational device
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
WO2002068453A3 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
WO2006026816A3 (en) Radio mobile unit location system
EP1510959A3 (en) Protein design automation for protein libraries
WO2004092727A3 (en) Compound libraries and methods for drug discovery
WO2005048196A3 (en) Object tracking within video images
AU2003255611A1 (en) Novel antiretroviral sulpholipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the hiv virus reverse transcriptase
WO2006019955A3 (en) Antiviral methods and compositions
WO2004087912A8 (en) Inhibitor proteins of a protease and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2483285

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003732434

Country of ref document: EP

Ref document number: 536412

Country of ref document: NZ

Ref document number: 2003238370

Country of ref document: AU

Ref document number: 3470/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004506369

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038146266

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003732434

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006035320

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10515241

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10515241

Country of ref document: US